Experienced & effective management

The Abgentis concept

Lloyd Czaplewski

Andy Muir

Dr Andy Muir of Midven Ltd joined the Abgentis Board in July 2012. He is a Director of Midven Ltd and Investment Director of the Rainbow Seed Fund and the Early Advantage fund. After an initial scientific career at Zeneca he went on to roles in research and business development at the medical device company Biocompatibles and then Vice President of Technology for a US start-up in disinfection of medical equipment. He started his career in VC with the £4m per annum Invention and Innovation seed capital fund at NESTA (the National Endowment for Science Technology and the Arts). He has a degree and a PhD in Chemistry from the University of Oxford.

Dr Lloyd Czaplewski FRSC, Abgentis' Founder & Director, brings an unusually wide breadth of experience that can make a significant impact on project progression. Leading biology and chemistry at strategic and technical levels, creating IP, managing portfolio investment decisions, building teams, successful fund-raising & due-diligence, business development & Company sale - the whole range of activities required to discover & translate Abgentis research into products.

While Vice-President R&D at Prolysis Limited, Lloyd led the structure-informed discovery and optimisation of DNA supercoiling inhibitors which were sold to Biota Holdings and subsequently sold on to Spero Therapeutics.

Lloyd Czaplewski created the Abgentis “fast-follower” concept: to fix the liabilities of a compound that was effective in the market but was not competitive due to resistance and side-effects.

Abgentis will deploy Lloyd's unique insight into the structure-activity relationships, microbiology, pharmacology and efficacy of antibacterial DNA supercoiling inhibitors to rapidly re-engineer and optimise, to improve the potency and resistance frequency and to minimise the side-effects to create an internationally competitive product.

Abgentis has clear evidence that a low-risk path to a novel and effective new broad-spectrum antibacterial has been identified and that the objectives of improved
potency, reduced resistance and a reduction in side-effects can be achieved.

Abgentis will focus on identifying a potential clinical candidate with compelling in vivo efficacy in models of infection to create a high value preclinical asset.

Virtual business

Minimal infrastructure & focus on project investment & progression are key.

Detailed project planning, budgeting and Lloyd's experience of placing and managing CROs enable Abgentis to operate a virtual business model.

Abgentis imited. Registered in England & Wales number 7967991. Registered office: Birmingham Research Park, Vincent Drive, Edgbaston, B15 2SQ. Address for correspondence: 123 Alexander Close, Abingdon, Oxfordshire, OX14 1XD

You are viewing the text version of this site.

To view the full version please install the Adobe Flash Player and ensure your web browser has JavaScript enabled.

Need help? check the requirements page.

Get Flash Player